Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.46 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.42 |
| ▸ | BCL2 | P10415 | 6/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 6/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6500385 | 0.92 | PPARG (0.45) | PPARGALOX5APBCL2MCL1 | |
| SCHEMBL6502208 | 0.90 | MCL1 (0.44) | PPARGALOX5APBCL2MCL1 | |
| SCHEMBL6488597 | 0.90 | BCL2 (0.50) | PPARGALOX5APBCL2MCL1 | |
| SCHEMBL6497504 | 0.87 | ALOX5AP (0.45) | PPARGALOX5AP | |
| SCHEMBL6301607 | 0.85 | PPARG (0.58) | PPARG | |
| SCHEMBL6492145 | 0.84 | PPARG (0.51) | PPARGALOX5APMCL1 | |
| SCHEMBL6491422 | 0.84 | PPARG (0.51) | PPARGALOX5APMCL1 | |
| SCHEMBL6308005 | 0.84 | PPARG (0.57) | PPARG | |
| SCHEMBL6487612 | 0.84 | PPARG (0.51) | PPARGALOX5APMCL1 | |
| SCHEMBL6498744 | 0.84 | PPARG (0.51) | PPARGALOX5APMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108686-A2 | BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | PPARG 233/4885ALOX5AP 4663/4885BCL2 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.